{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:31:40Z","timestamp":1790937100469,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA242003"],"award-info":[{"award-number":["R01 CA242003"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01241191"],"award-info":[{"award-number":["R01241191"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e37829","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T12:38:58Z","timestamp":1726317538000},"page":"e37829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeted degradation of specific TEAD paralogs by small molecule degraders"],"prefix":"10.1016","volume":"10","author":[{"given":"Hui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Gridnev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netanya","family":"Schlamowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuntala","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-2452","authenticated-orcid":false,"given":"Jyoti R.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e37829_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e37829_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo pathway in organ size control, tissue homeostasis, and cancer","volume":"163","author":"Yu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e37829_bib3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","article-title":"The Hippo signalling pathway and its implications in human health and diseases","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e37829_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-genet-120417-031621","article-title":"The Hippo signaling network and its biological functions","volume":"52","author":"Misra","year":"2018","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.heliyon.2024.e37829_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164242","article-title":"Emerging principles in the transcriptional control by YAP and TAZ","volume":"13","author":"Lopez-Hernandez","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e37829_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41568-019-0168-y","article-title":"YAP and TAZ: a signalling hub of the tumour microenvironment","volume":"19","author":"Zanconato","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heliyon.2024.e37829_bib7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","article-title":"Comprehensive molecular characterization of the Hippo signaling pathway in cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e37829_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.trecan.2020.04.004","article-title":"The Hippo pathway as a driver of select human cancers","volume":"6","author":"Kulkarni","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.heliyon.2024.e37829_bib9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e37829_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.coph.2016.05.002","article-title":"YAP\/TAZ as therapeutic targets in cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"YAP\/TAZ at the roots of cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2024.e37829_bib12","first-page":"83","article-title":"The role of Hippo pathway in cancer stem cell biology","volume":"41","author":"Park","year":"2018","journal-title":"Mol. Cell."},{"key":"10.1016\/j.heliyon.2024.e37829_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ signaling and resistance to cancer therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.heliyon.2024.e37829_bib14","doi-asserted-by":"crossref","first-page":"114576","DOI":"10.18632\/oncotarget.23051","article-title":"YAP regulates PD-L1 expression in human NSCLC cells","volume":"8","author":"Miao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e37829_bib15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bbrc.2017.07.007","article-title":"Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma","volume":"491","author":"Lee","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2024.e37829_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma","volume":"6","author":"Kim","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2024.e37829_bib17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/cells8060600","article-title":"Regulation of TEAD transcription factors in cancer biology","volume":"8","author":"Huh","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e37829_bib18","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tibs.2017.09.003","article-title":"Regulation of the Hippo pathway transcription factor TEAD","volume":"42","author":"Lin","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.heliyon.2024.e37829_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nchembio.2036","article-title":"Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway","volume":"12","author":"Chan","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107809","article-title":"Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of Hippo pathway signaling","volume":"31","author":"Holden","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e37829_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114684","article-title":"A chemical perspective on the modulation of TEAD transcriptional activities: recent progress, challenges, and opportunities","volume":"243","author":"Lou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e37829_bib22","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.3390\/cells10102715","article-title":"Recent therapeutic approaches to modulate the Hippo pathway in oncology and regenerative medicine","volume":"10","author":"Barry","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e37829_bib23","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.80210","article-title":"Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode","volume":"11","author":"Hu","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.heliyon.2024.e37829_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1021823","article-title":"Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity","volume":"12","author":"Gridnev","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/acs.jmedchem.2c01189","article-title":"Small-molecule cyanamide pan-tead\u00b7yap1 covalent antagonists","volume":"66","author":"Bum-Erdene","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e37829_bib26","doi-asserted-by":"crossref","first-page":"9206","DOI":"10.1021\/acs.jmedchem.2c00403","article-title":"Optimization of TEAD P-site binding fragment hit into in vivo active lead MSC-4106","volume":"65","author":"Heinrich","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e37829_bib27","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1021\/acs.jmedchem.2c01548","article-title":"Structure-based design of Y-shaped covalent TEAD inhibitors","volume":"66","author":"Lu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e37829_bib28","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e37829_bib29","doi-asserted-by":"crossref","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2023-CT006","volume":"83","author":"Yap","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e37829_bib30","first-page":"4399","article-title":"The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma","volume":"10","author":"Kaneda","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e37829_bib31","doi-asserted-by":"crossref","first-page":"TPS3168","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3168","article-title":"A phase 1, first-in-human study of Ik-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors","volume":"40","author":"Tolcher","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1158\/1538-7445.AM2023-501","article-title":"Discovery of BPI-460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrations","volume":"83","author":"Shen","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e37829_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78810","article-title":"Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling","volume":"11","author":"Fan","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.heliyon.2024.e37829_bib34","first-page":"OF1","article-title":"A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models","author":"Hillen","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e37829_bib35","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.3c00386","article-title":"Development of HC-258, a covalent acrylamide TEAD inhibitor that reduces gene expression and cell migration","author":"Fnaiche","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.heliyon.2024.e37829_bib36","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.apsb.2021.04.015","article-title":"Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3","volume":"11","author":"Lu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.heliyon.2024.e37829_bib37","doi-asserted-by":"crossref","first-page":"11972","DOI":"10.1021\/acs.jmedchem.0c01275","article-title":"Discovery of covalent inhibitors targeting the transcriptional enhanced associate domain central pocket","volume":"63","author":"Karatas","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e37829_bib38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.chembiol.2018.11.010","article-title":"Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEAD\u22c5Yap protein-protein interaction","volume":"26","author":"Bum-Erdene","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.stem.2020.03.002","article-title":"Lats1\/2 sustain intestinal stem cells and wnt activation through TEAD-dependent and independent transcription","volume":"26","author":"Li","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.heliyon.2024.e37829_bib40","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/s41467-022-34559-0","article-title":"Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells","volume":"13","author":"Sun","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e37829_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.872729","article-title":"Overcoming cancer drug resistance utilizing PROTAC Technology","volume":"10","author":"Burke","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e37829_bib43","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.heliyon.2024.e37829_bib44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e37829_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e37829_bib47","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.chembiol.2023.06.020","article-title":"The rise of degrader drugs","volume":"30","author":"Teng","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heliyon.2024.e37829_bib49","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.heliyon.2024.e37829_bib50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib51","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acscentsci.3c00395","article-title":"Proximity-based modalities for biology and medicine","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.heliyon.2024.e37829_bib52","doi-asserted-by":"crossref","first-page":"10122","DOI":"10.1021\/acs.jmedchem.3c00079","article-title":"Exploitation of proximity-mediated effects in drug discovery: an update of recent research highlights in perturbing pathogenic proteins and correlated issues","volume":"66","author":"Zhao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e37829_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e37829_bib54","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted protein degradation: from chemical biology to drug discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) \u2014 past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib56","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1021\/acs.jmedchem.2c00397","article-title":"Selectivity through targeted protein degradation (TPD)","volume":"65","author":"Gopalsamy","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e37829_bib57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.chembiol.2023.01.007","article-title":"Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation","volume":"30","author":"Rosenberg","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib58","doi-asserted-by":"crossref","first-page":"14276","DOI":"10.1021\/acs.jmedchem.2c01159","article-title":"Blocking non-enzymatic functions by PROTAC-mediated targeted protein degradation","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e37829_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e37829_bib60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib61","series-title":"Bicyclic Compounds","author":"Konradi","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e37829_bib62","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e37829_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202308292","article-title":"Proteomics-based discovery of first-in-class chemical probes for programmed cell death protein 2 (PDCD2)","volume":"62","author":"Ji","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.heliyon.2024.e37829_bib64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/acsmedchemlett.4c00029","article-title":"Design, synthesis, and bioevaluation of transcriptional enhanced assocciated domain (TEAD) PROTAC degraders","volume":"15","author":"Li","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.heliyon.2024.e37829_bib65","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e37829_bib66","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1021\/acs.jmedchem.1c00517","article-title":"Discovery of a novel BCL-XL PROTAC degrader with enhanced BCL-2 inhibition","volume":"64","author":"Pal","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024138601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024138601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:22:46Z","timestamp":1790713366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024138601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":66,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024138601"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37829","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted degradation of specific TEAD paralogs by small molecule degraders","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e37829"}}